VGL-101 is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of VGL-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for VGL-101 is expected to reach an annual total of $49 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vigil Neuroscience Overview
Vigil Neuroscience is a biotechnology company that discovers and develops microglial therapeutics for the treatment of neurodegenerative diseases. The company is investigating its lead candidate VGL101, a fully human monoclonal antibody for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy (cALD) and Alzheimer’s disease. It is also evaluating small molecule term2 agonist, a microglial receptor protein targeting microangiopathies and Alzheimer’s disease. Vigil Neuroscience utilizes modern neuroscience drug development tools to develop precision-based therapies. The company works in collaboration with academic organizations, and pharmaceutical and biotechnology companies to develop its products. Vigil Neuroscience is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$68.9 million in FY2022, compared to an operating loss of US$42.4 million in FY2021. The net loss of the company was US$68.3 million in FY2022, compared to a net loss of US$43.3 million in FY2021.
For a complete picture of VGL-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.